Indoco launches Favipiravir under brand name FEVINDO 400 in India
Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance.
Mumbai: Drugmaker, Indoco Remedies, has recently announced the launch of FEVINDO (Favipiravir) 400 mg Tablets in India.
Fevindo ‐ 400 (Favipiravir) is an antiviral drug, effective against the RNA‐based influenza virus.
The drug has been approved by DCGI in the treatment of Covid‐19.
Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance.
Ms. Aditi Kare Panandikar, Managing Director ‐ Indoco Remedies Ltd. commented, "The Covid‐19 crisis has created vast disruption to life in India and all over the globe. As part of pharma industry, we have been able to do our bit in prevention of Covid‐19 with our brands Karvol Plus, ATM, Febrex Plus and Rexidin SRS Mouthwash. With the launch of FEVINDO, we are taking the next step from prevention to the treatment of Covid‐19."
Fevindo ‐ 400 (Favipiravir) will be made available at all government approved COVID care centres and selected medical practitioners across the country.
In addition to Fevindo, Indoco has two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle and Immunity booster chewable tablets with Zinc, Vitamin C and Vitamin D.
To ensure accelerated access to Fevindo 400, Indoco has set up the following helplines:
Toll free helpline ‐ 1800 212 7188
WhatsApp / SMS ‐ 9833 85 85 85
Email helpline – fevindo@indoco.com
Read also: Indoco Remedies Blood-thinner Apixaban gets USFDA green flag
Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research‐oriented pharma Company with presence in 55 countries.
The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state‐of‐the‐art R&D Centre and a CRO facility
Read also: Indoco Remedies gets USFDA nod to Olanzapine Tablets to treat schizophrenia, bipolar disorder
